US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Axonics, Inc. - Common Stock
(NQ:
AXNX
)
70.98
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axonics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Axonics® Announces Proposed Public Offering of Common Stock
May 11, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics® Reports First Quarter 2021 Financial Results
May 06, 2021
From
Axonics, Inc.
Via
Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference
April 22, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
April 15, 2021
From
Axonics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
↗
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
↗
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
↗
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
↗
April 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
↗
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
